Home

Effect of specific immunotherapy of carcinoma of uterine cervix on the state of cellular immunity

Written by Kenbaeva D.K., Manambaeva Z.A., Lazarev A.F

  UDK: 618.146-006.6-085.37:612.017 | Pages: 85–88 | Full text PDF | Open PDF 

Annotation:

Background. The object of research is to evaluate the efficacy of the specific immunotherapy of carcinoma of uterine cervix in a combination with the radiation therapy.
Methods. The research covers 81 patients having cervical cancer from IIB to III grades. Conducted combined radiotherapy (41 cases) and combined treatment (40 cases): radiation therapy and specific immunotherapy, i.e. the reinfusions of lymphocytes after incubation with homogenates of the tumor tissue in vitro and addition of interleukin-2. Detected indicators of cellular immunity.
Results. Significant increment of indicators due to the combined therapy registered exclusively for the absolute content of natural killer cells in IIB grade and for the relative content of killer T cells in III grade of the cancer. Normalization of the level of lymphocyte of all examined phenotypes in blood of the patients having carcinoma of uterine cervix failed to be achieved.
Conclusions. Based on the results, the conclusion is that the efficacy of the used methods of stimulation of the antitumour immunity was insufficient and it suggests developing additional ways to activate the cellular mechanisms in vivo.

Links to authors:

D.K. Kenbaeva1, Z.A. Manambaeva2, A.F. Lazarev3
1 Astana Municipal Oncological Center (7 Manas St. Astana 010000 Republic of Kazakhstan)
2 Semey State Medical University (103 Abay Kunanbaev St. Semey 007140 Republic of Kazakhstan)
3 Altai Regional Oncological Center (77, Nikitina St. 656000
Barnaul Russian Federation)

1. Glantz S. Mediсal and biological statistics / translation from English. M.: Practice, 1998. 459 p.
2. Aguilar L.K., Guzik B.W., Aguilar-Cordova E. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development // J. Cell. Biochem. 2011. Vol. 112, No. 8. P. 1969–1977.
3. Berzofsky J.A., Terabe M., Wood L.V. Strategies to use immune modulators in therapeutic vaccines against cancer // Semin. Oncol. 2012. Vol. 39, No. 3. P. 348–357.
4. Inamoto T., Azuma H. Immunotherapy of genitourinary malignancies // J. Oncol. 2012. Article ID 397267.
5. Gajewski T.F. Cancer immunotherapy // Mol. Oncol. 2012. Vol. 6, No. 2. P. 242–250.
6. Jordanova E.S., Gorter A., Ayachi O. [et al.]. Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/ regulatory T-cell ratio: which variable determines survival of cervical cancer patients? // Clin. Cancer Res. 2008. Vol. 14, No. 7. P. 2028–2035.
7. Krieger N., Bassett M.T., Gomez S.L. Breast and cervical cancer in 187 countries between 1980 and 2010 // Lancet. 2012. Vol. 379, No. 9824. P. 1391–1392.
8. Pandolfi F., Cianci R., Pagliari D. [et al.]. The immune response to tumors as a tool toward immunotherapy // Clin. Dev. Immunol. 2011. Article ID 894704.
9. Reinis M., Stepanek I., Simova J. [et al.]. Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines // Int. J. Oncol. 2010. Vol. 36, No. 3. P. 545–551.
10. Van den Broek M., von Boehmer L., Knuth A. Developments in cancer immunotherapy // Dig. Dis. 2010. Vol. 28, No. 1. P. 51–56.

PUBLISHER: "MEDITSYNA DV"

Founded in 1997  |  Editions in a year: 4, Articles in one issue: 30 |  ISSN of print version: 1609-1175  |  Ind.: 18410 (Agency "Rospechat’")  |  Edition: 1000 c.